Alkeus Pharmaceuticals | Evaluate

October 26, 2022

Looking for winners in geographic atrophy

NGM’s NGM621 now looks like a dead end, but there are plenty of others hoping for a piece of this market, including Roche and Lineage.

September 10, 2021

Apellis finds that one of its twins is evil

A hit and a miss with pegcetacoplan in late-stage trials leaves Apellis with shrinking prospects.

June 23, 2021

No land grab for Gemini in geographic atrophy

Pivotal development of GEM103 is set to proceed, but the phase 2 result is a cautionary tale – not only for Gemini.